2030 年までの北米オピオイド市場予測 - 地域別分析 - 製品別 (即効性短時間作用型オピオイドと徐放性長時間作用型オピオイド)、用途別 (疼痛管理、麻酔、下痢抑制、咳抑制、依存症治療など)、投与経路別 (経口、注射、経皮パッチ)、流通チャネル別 (病院薬局と小売薬局)
高齢者人口の増加が北米のオピオイド市場を活性化
高齢者の大多数は慢性的な痛みを抱えて生活しており、その結果、日常生活を営むための体力が低下しています。高齢者は、骨や関節の障害、関節炎、がん、その他の痛みを引き起こす慢性疾患に広く苦しんでいます。2018年2月の世界保健機関（WHO）のデータによると、高齢者人口は2015年の12％と比較して2050年までに22％増加すると推定されています。このデータでは、低所得国と中所得国がこの急増のほぼ80％を占めるとも述べられています。米国、カナダ、英国、フランス、ドイツ、日本などの先進国や、中国、インド、韓国などの発展途上国でも、医療施設の改善や医療サービスの向上により、高齢者人口が大幅に増加しており、これらの地域では平均寿命が延びています。NCBIジャーナルによると、強力なオピオイドの処方は高齢者層でより一般的であり、この年齢層で最も急速に増加しています。米国医療研究・品質保証庁によると、2020年から2021年にかけて、米国では65歳以上の成人の平均12.8%が少なくとも1回の外来オピオイド処方を受け、4.4%が4回以上のオピオイド処方を受けていました。さらに、貧困層（6.1%）、低所得層（6.6%）、中所得層（5.2%）に該当する高齢者は、高所得層（2.6%）にグループ化された高齢者よりも、2020年から2021年の間に4回以上のオピオイド処方箋を受け取る可能性が高かった。このように、世界中で増加する高齢者人口が、北米のオピオイド市場の成長を牽引している。
北米のオピオイド市場の概要
オピオイドベースの鎮痛薬は、中等度から重度の関節炎の痛みを持つ患者の整形外科治療の基礎です。 2023年10月に疾病管理予防センター（CDC）が関節炎の有病率について発表したデータによると、2019年から2021年の間に米国の成人の約21.2％（つまり5,320万人）が医師の診断を受けた関節炎を患っており、その数は2040年までに7,840万人に達すると予測されています。関節炎の症例が増加するにつれて、疼痛管理のためのオピオイドの需要が高まっています。
一方、オピオイドの過剰摂取の症例の急増は、北米のオピオイド市場の成長に影響を与えています。オピオイドの過剰摂取に関する世界保健機関（WHO）の統計によると、2019年に米国では薬物の過剰摂取により70,630人が死亡しました。 CDCはまた、1999年から2021年の間に国内で約28万人が処方オピオイドの過剰摂取で死亡したと推定しています。2021年には、国内のオピオイド過剰摂取による死亡者の約21％が処方オピオイドに関連していました。オピオイド過剰摂取の症例数と死亡率の増加により、CDCは2017年にこの状況を全国的な公衆衛生上の緊急事態と分類しました。この状況はオピオイド危機とも呼ばれ、オピオイド薬物のクラスに起因する過剰使用、誤用/乱用、過剰摂取による死亡の急増が含まれていました。オピオイド危機の状況に対処し、意図的な乱用を防ぐために、食品医薬品局（FDA）は乱用防止処方（ADF）を使用した処方オピオイドの開発を奨励しています。 FDAは2021年3月にヒドロコドン酒石酸塩を承認しました。これはADFを備えたFDA承認の初のジェネリックオピオイドであり、噛んでから経口摂取、粉砕して鼻から吸い込む、または注射することで薬物の乱用を減らすことが期待される特性を持っています。さらに、満たされていない医療ニーズに対処するために、米国では医薬品の承認が増加しています。したがって、北米のオピオイド市場のプレーヤーは、製品ポートフォリオを拡大するための製品承認や進歩、市場シェアを向上させるための拡大や合併などの戦略に重点を置いています。2020年3月、Trevena、Inc.は、特に静脈内オピオイドを必要とするほど痛みがひどい場合の成人の中等度から重度の急性疼痛の管理に適応するオピオイド作動薬であるOLINVYK（オリセリジン）のFDA承認を取得しました。
北米のオピオイド市場の収益と2030年までの予測（百万米ドル）
北米のオピオイド市場のセグメンテーション
北米のオピオイド市場は、製品、用途、投与経路、流通チャネル、および国に分類されています。
製品に基づいて、北米のオピオイド市場は、即放性短時間作用型オピオイドと徐放性長時間作用型オピオイドに分かれています。即放性短時間作用型オピオイドセグメントは、2022年に大きな市場シェアを占めました。即放性短時間作用型オピオイドは、オキシコドン、ヒドロコドン、トラマドール、コディン、プロポキシフェンなどにさらに細分化されています。徐放性長時間作用型オピオイドは、オキシコドン、フェンタニル、モルヒネ、メタドンなどにさらに細分化されています。
用途別に見ると、北米のオピオイド市場は、疼痛管理、麻酔、下痢抑制、咳抑制、依存症治療などに分類されています。疼痛管理セグメントは2022年に最大の市場シェアを占めました。
投与経路別に見ると、北米のオピオイド市場は経口、注射、経皮パッチに分類されています。経口セグメントは2022年に最大の市場シェアを占めました。
流通チャネル別に見ると、北米のオピオイド市場は病院薬局と小売薬局に分かれています。病院薬局セグメントは2022年に大きな市場シェアを占めました。
国別に見ると、北米のオピオイド市場は米国、カナダ、メキシコに分かれています。 2022年、北米のオピオイド市場シェアは米国が独占しました。
Purdue Pharma LP、Endo International plc、Mallinckrodt Plc、Collegium Pharmaceutical Inc、Neuraxpharm Pharmaceuticals SL、Hikma Pharmaceuticals Plc、Rusan Pharma Ltd、Trevena Inc、Teva Pharmaceutical Industries Ltdは、北米のオピオイド市場で事業を展開している大手企業の一部です。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Opioids Market - Key Market Dynamics
4.1 North America Opioids Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Surging Chronic Pain Incidence
4.2.2 Increasing Geriatric Population
4.3 Market Restraints
4.3.1 Increasing Drug Abuse
4.4 Market Opportunities
4.4.1 Strategic Initiatives by Market Players
4.5 Future Trends
4.5.1 Government Initiatives Focusing on Development of Medication to Prevent and Treat Opioid Overdose and Disorder
4.6 Impact of Drivers and Restraints:
5. Opioids Market - North America Analysis
5.1 North America Opioids Market Revenue (US$ Million), 2020-2030
5.2 North America Opioids Market Forecast Analysis
6. North America Opioids Market Analysis - by Product
6.1 Immediate Release Short Acting Opioid
6.1.1 Overview
6.1.2 Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
6.1.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
6.2 Extended Release Long-Acting Opioid
6.2.1 Overview
6.2.2 Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
6.2.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
7. North America Opioids Market Analysis - by Application
7.1 Pain Management
7.1.1 Overview
7.1.2 Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Anesthesia
7.2.1 Overview
7.2.2 Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Diarrhea Suppression
7.3.1 Overview
7.3.2 Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cough Suppression
7.4.1 Overview
7.4.2 Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.5 De-Addiction
7.5.1 Overview
7.5.2 De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Opioids Market Analysis - by Route of Administration
8.1 Oral
8.1.1 Overview
8.1.2 Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Injectable
8.2.1 Overview
8.2.2 Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Transdermal Patch
8.3.1 Overview
8.3.2 Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Opioids Market Analysis - by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Opioids Market - Country Analysis
10.1 North America Opioids Market - Country Analysis
10.1.1 North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
10.1.1.1 North America Opioids Market - Revenue and Forecast Analysis - by Country
10.1.1.2 United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 United States: North America Opioids Market Breakdown, by Product
10.1.1.2.2 United States: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.2.3 United States: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.2.4 United States: North America Opioids Market Breakdown, by Application
10.1.1.2.5 United States: North America Opioids Market Breakdown, by Route of Administration
10.1.1.2.6 United States: North America Opioids Market Breakdown, by Distribution Channel
10.1.1.3 Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Canada: North America Opioids Market Breakdown, by Product
10.1.1.3.2 Canada: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.3.3 Canada: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.3.4 Canada: North America Opioids Market Breakdown, by Application
10.1.1.3.5 Canada: North America Opioids Market Breakdown, by Route of Administration
10.1.1.3.6 Canada: North America Opioids Market Breakdown, by Distribution Channel
10.1.1.4 Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Mexico: North America Opioids Market Breakdown, by Product
10.1.1.4.2 Mexico: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.4.3 Mexico: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.4.4 Mexico: North America Opioids Market Breakdown, by Application
10.1.1.4.5 Mexico: North America Opioids Market Breakdown, by Route of Administration
10.1.1.4.6 Mexico: North America Opioids Market Breakdown, by Distribution Channel
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies in Opioids Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Purdue Pharma L.P.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Endo International plc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Mallinckrodt Plc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Collegium Pharmaceutical, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Neuraxpharm Pharmaceuticals SL
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Hikma Pharmaceuticals Plc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Rusan Pharma Ltd
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Trevena, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Teva Pharmaceutical Industries Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
List of Tables
Table 1. North America Opioids Market Segmentation
Table 2. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 4. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 5. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 6. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 7. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 8. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 9. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 10. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 11. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 12. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 13. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 14. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 15. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 17. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 18. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 19. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 20. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 21. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 22. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 23. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 24. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 26. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 27. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 28. Recent Organic Growth Strategies in Opioids Market
Table 29. Recent Inorganic Growth Strategies in the Opioids Market
Table 30. Glossary of Terms, Opioids Market
List of Figures
Figure 1. North America Opioids Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Opioids Market Revenue (US$ Million), 2020-2030
Figure 4. North America Opioids Market Share (%) - by Product (2022 and 2030)
Figure 5. Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. North America Opioids Market Share (%) - by Application (2022 and 2030)
Figure 8. Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Opioids Market Share (%) - by Route of Administration (2022 and 2030)
Figure 15. Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 19. Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Opioids Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 22. North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 23. United States: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. Canada: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
Figure 26. Growth Strategies in Opioids Market
- Purdue Pharma LP
- Endo International plc
- Mallinckrodt Plc
- Collegium Pharmaceutical Inc
- Neuraxpharm Pharmaceuticals SL
- Hikma Pharmaceuticals Plc
- Rusan Pharma Ltd
- Trevena Inc
- Teva Pharmaceutical Industries Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America opioids market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America opioids market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America opioids market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.